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Background:  Transcatheter aortic valve implantation (TAVI) is emerging as an important therapeutic tool in aortic stenosis (AS), but its effects 
over time on LV hemodynamics as compared with standard therapies in inoperable patients have not been well quantified.
Methods:  358 inoperable patients with critical AS (AVA 0.6+.2 cm2; mean gradient 44+15 mmHg) were randomized to either TAVI or standard 
therapy (STD) which included balloon valvuloplasty (BAV) in 84%. Baseline, 7d, 30d, 6mo and 1y echoes were analyzed by a single blinded observer 
with excellent reproducibility (ICC .92-.99; Kappa .58-.85). Paired sample T-tests were used to evaluate changes over time.
Results:  TAVI was associated with an immediate and sustained increase in valve area and decrease in mean gradient (to 1.6+.5 cm2 and 13+11 
mmHg at 1 y), with an associated immediate increase in ejection fraction (54+13 to 57+11%; p<.01) and a reduction in mitral regurgitation 
(p<.001). These parameters were unchanged in STD, depite frequent BAV. LV mass index decreased over time only in TAVI (from 148+39 at baseline 
to 130+39 gm/m2 at 1 y, p<.0001) becoming significant at 6 mo, while modest reductions in concentric remodeling were not significant (.74+ .51 
to .65+ .59; p=.15). At 1 y the reduction in valve gradient was modestly related to the reduction in LV mass index (r=0.22; p= 0.09).
There were no instances of mod-severe bioprosthetic AS at 1 y in TAVI pts. Although there was moderate/severe paravalvular regurgitation (AR) 
in 11% of TAVI, total AR (paravalvular plus transvalvular) did not differ between the groups (15% TAVI, 17% STD). In TAVI, total AR was related to 
increasing LV diastolic volume index over time r=0.44; p=.002).
Conclusions:  Relief of pressure overload with TAVI in inoperable AS patients is associated with beneficial hemodynamic effects and regression 
of hypertrophy, not seen with standard therapy including balloon valvuloplasty. Longer term clinical and echocardiographic monitoring is needed to 
determine the future role and durability of TAVI.
